Detail akcie Halozyme Thrp online

Business Summary: Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Halozyme Therapeutics, Inc. revenues increased 42% to $376.7M. Net income increased 27% to $150M. Revenues reflect Royalties segment increase of 43% to $240.7M, Roche (rHuPH20) segment increase from $27M to $73.5M. Net income was partially offset by Amortization of intangibles increase of 66% to $29.5M (expense), Selling, general and administrative - Ba increase of 33% to $46.3M (expense).